Sgroi Michael D, Narayan Raja R, Lane John S, Demirjian Aram, Kabutey Nii-Kabu, Fujitani Roy M, Imagawa David K
From the Division of Vascular and Endovascular Surgery and Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, University of California, Irvine, Calif.
From the Division of Vascular and Endovascular Surgery and Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, University of California, Irvine, Calif.
J Vasc Surg. 2015 Feb;61(2):475-80. doi: 10.1016/j.jvs.2014.09.003. Epub 2014 Oct 29.
Previous studies have proved the feasibility of performing a pancreaticoduodenectomy (Whipple operation) in patients with portal vein-superior mesenteric vein and hepatic artery invasion. We report our institutional experience with the use of a variety of vascular reconstructive methods during pancreatic resections for adenocarcinoma.
A retrospective review was performed identifying all patients undergoing a Whipple operation or total pancreatectomy procedure from January 2003 to December 2013. All venous (portal vein-superior mesenteric vein) and arterial (superior mesenteric artery-hepatic artery) reconstructions were extracted and reviewed to determine survival and perioperative complications.
During the 10-year study period, 270 Whipple and total pancreatectomy procedures were performed, of which 183 were for adenocarcinoma of the pancreas. Of the 183 operations, a total of 60 (32.8%) vascular reconstructions were found, 49 venous and 11 arterial. Venous reconstruction included 37 (61.7%) primary repairs, four (6.7%) reconstructions with CryoVein (CryoLife, Inc, Kennesaw, Ga), three (5.0%) repairs with autologous vein patch, three (5.0%) autologous saphenous reconstructions, and two (3.33%) portacaval shunts. In addition, there were 11 (18.3%) arterial reconstructions (seven hepatic artery and four superior mesenteric artery). The 1-year survival for all reconstructions was 71.1%, which is equivalent to T3 lesions that did not receive vascular reconstruction (70.11%), with a median survival time of 575.28 days and 12 patients still alive. Survival time was comparable with each type of venous reconstruction, averaging 528 days (11 of 49 patients still alive). There was a total thrombosis rate of seven of 60 (11.6%), all of which were portal vein thrombosis: three in the primary repair group and four delayed thromboses seen in primary repair, CryoVein repair, and vein patch repair. There was no thrombosis in any patients after arterial reconstruction.
An aggressive approach for stage II pancreatic cancers with venous or arterial invasion can be performed with comparable results when it is executed by an experienced institution with skilled oncologic and vascular surgeons.
既往研究已证实对门静脉-肠系膜上静脉及肝动脉受侵患者施行胰十二指肠切除术(惠普尔手术)的可行性。我们报告本机构在胰腺癌切除术中使用多种血管重建方法的经验。
进行一项回顾性研究,确定2003年1月至2013年12月期间所有接受惠普尔手术或全胰切除术的患者。提取并分析所有静脉(门静脉-肠系膜上静脉)和动脉(肠系膜上动脉-肝动脉)重建情况,以确定生存率和围手术期并发症。
在10年研究期间,共施行270例惠普尔手术和全胰切除术,其中183例为胰腺癌手术。在这183例手术中,共发现60例(32.8%)血管重建,49例静脉重建和11例动脉重建。静脉重建包括37例(61.7%)一期修复、4例(6.7%)使用CryoVein(CryoLife公司,美国佐治亚州肯尼索)重建、3例(5.0%)自体静脉补片修复、3例(5.0%)自体大隐静脉重建以及2例(3.33%)门腔分流术。此外,有11例(18.3%)动脉重建(7例肝动脉和4例肠系膜上动脉)。所有重建患者的1年生存率为71.1%,与未接受血管重建的T3期病变(70.11%)相当,中位生存时间为575.28天,12例患者仍存活。各类型静脉重建的生存时间相近,平均为528天(49例患者中有11例仍存活)。60例中有7例(11.6%)发生血栓形成,均为门静脉血栓形成:一期修复组3例,一期修复、CryoVein修复和静脉补片修复中出现4例延迟血栓形成。动脉重建后所有患者均未发生血栓形成。
对于有静脉或动脉侵犯的II期胰腺癌,由经验丰富的机构中技术娴熟的肿瘤外科医生和血管外科医生实施积极手术,可取得相似的结果。